Publication

ASN •
8 November, 2025 •
•

Pegcetacoplan for 52 weeks results in sustained proteinuria reduction to remission (≤0.5 g/g) and normalization (≤0.2 g/g): Phase 3 VALIANT trial

Carla M Nester, Fadi Fakhouri, Daniel P Gale, Andrew S Bomback, Christoph Licht, Giuseppe Remuzzi, Nicole CAJ Van de Kar, Katie Gordon, Anwesha Mukherjee, Johan Szamosi, Lucía Quintana-Gallardo, Matthew C Pickering

Available materials

Oral Presentation

Publication

ASN •
7 November, 2025 •
•

"Tiredness…That’s the main thing, this is why I work part time.": A thematic analysis of patient perspectives on care and unmet needs in C3G and primary IC-MPGN

Sanya Norouzi, Mingyi Huang, Carly Rich, Katie Gordon, Lucía Quintana-Gallardo, Elizabeth A Holdsworth, Fernando Caravaca-Fontán

Available materials

Poster

Publication

ASN •
7 November, 2025 •
•

Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons

Bradley P Dixon, Andrew S Bomback, Carly Rich, Mingyi Huang, Piotr Wojciechowski, Rose Chang, Fernando Caravaca-Fontán, Fadi Fakhouri

Available materials

Poster

Publication

Management of Uncontrolled Gout Among Nephrology Professionals: Findings from a Medical Chart Audit

Pegcetacoplan for 52 weeks results in sustained proteinuria reduction to remission (≤0.5 g/g) and normalization (≤0.2 g/g): Phase 3 VALIANT trial

"Tiredness…That’s the main thing, this is why I work part time.": A thematic analysis of patient perspectives on care and unmet needs in C3G and primary IC-MPGN

Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons

Nanoencapsulated Sirolimus Plus Pegadricase Reduced Disease Burden in Patients With Uncontrolled Gout: Results From the Phase 3 DISSOLVE Trials

Nanoencapsulated Sirolimus Plus Pegadricase (NASP) Demonstrates a Reduction in Gout Flares: Results From the Phase 3 DISSOLVE Studies

Characterization of Infusion Reactions Within 1 Hour of Treatment With Nanoencapsulated Sirolimus Plus Pegadricase: Pooled Results From the Phase 3 DISSOLVE I and DISSOLVE II Trials

Reduction in Tophi Observed in Patients With Uncontrolled Gout Treated With NASP: Results From Phase 3 DISSOLVE Studies